Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure

European Journal of Heart Failure

Volumn 10, Issue 5, 2008, Pages 463-466

  Young, Joanna M ^a   Strey, Christopher H ^a   George, Peter M ^b   Florkowski, Christopher M ^a,b   Sies, Christiaan W ^b   Frampton, Christopher M ^c   Scott, Russell S ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Asymmetric dimethylarginine; Chronic heart failure; Endothelial function; Left ventricular dysfunction; Statin treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ARGININE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; SPIRONOLACTONE;

ADULT; ANALYTIC METHOD; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; HEART EJECTION FRACTION; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ARGININE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 42749096663     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.03.010     Document Type: Article

References (21)

1. Bauersachs J., and Schafer A. Endothelial dysfunction in heart failure: mechanisms and therapeutic approaches. Curr Vasc Pharmacol 2 (2004) 115-124
2. Katz S.D., Schwarz M., Yuen J., and LeJemtel T.H. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 88 (1993) 55-61
3. Usui M., Matsuoka H., Miyazaki H., Ueda S., Okuda S., and Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62 (1998) 2425-2430
4. Duckelmann C., Mittermayer F., Haider D.G., Altenberger J., Eichinger J., and Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 27 (2007) 2037-2042
5. Boger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Annal Med 38 (2006) 126-136
6. Bode-Boger S.M., Scalera F., and Ignarro L.J. The l-arginine paradox: importance of the l-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther 114 (2007) 295-306
7. Dimitrow P.P., Undas A., Bober M., Tracz W., and Dubiel J.S. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep 59 (2007) 715-720
8. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
9. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
10. Laufs U., and Liao J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273 (1998) 24266-24271
11. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
12. Teerlink T., Nijveldt R.J., de Jong S., and van Leeuwen P.A.M. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303 (2002) 131-137
13. Celermajer D.S., Sorensen K.E., Gooch V.M., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340 (1992) 1111-1115
14. Watts G.F., O'Brien S.F., Silvester W., and Millar J.A. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Lond) 91 (1996) 567-573
15. Lu T.M., Ding Y.A., Leu H.B., Yin W.H., Sheu W.H.H., and Chu K.M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 94 (2004) 157-161
16. Tousoulis D., Antoniades C., Vassiliadou C., et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 7 (2005) 1126-1132
17. Keith M., Geranmayegan A., Sole M.J., et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31 (1998) 1352-1356
18. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., and Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
19. Chen M.S., Xu F.P., Wang Y.Z., et al. Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 37 (2004) 889-896
20. Paiva H., Laakso J., Laine H., Laaksonen R., Knuuti J., and Raitakari O.T. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 40 (2002) 1241-1247
21. Valkonen V.P., Laakso J., Paiva H., et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?. Atheroscler Suppl 4 (2003) 19-22